Clinical Research Focus. 28th Edition

Anticipating ASCO: Key Trends in Oncology Clinical Research

The upcoming ASCO Conference, an essential gathering for oncology professionals, where leading experts will discuss the latest advancements in cancer research and treatment. Cromos Pharma’s CEO, Vlad Bogin, will attend to share his insights. In his new article, Dr. Bogin explores innovative trends and future directions in oncology research.  

Please follow the link to learn more.

FDA Approves New Antibiotic Zevtera for Serious Bacterial Infections

The FDA has approved Zevtera, a new antibiotic for treating severe bacterial infections like Staphylococcus aureus bloodstream infections and community-acquired bacterial pneumonia. Developed by Basilea Pharmaceutica, Zevtera offers an effective treatment option tested across several rigorous trials.

Please follow the link to learn more.

Promising Results for Prasinezumab in Early-Stage Parkinson’s Disease

Recent findings from the PASADENA phase 2 study indicate that prasinezumab, a monoclonal antibody targeting α-synuclein, may slow progression of motor symptoms in early-stage Parkinson’s disease, particularly among rapidly progressing patients. Despite not meeting its primary endpoint, the treatment showed significant potential in specific patient subgroups.

Please follow the link to learn more.

NIH Develops AI Tool to Enhance Precision in Cancer Treatment

Researchers at the NIH have introduced a groundbreaking AI tool capable of using single-cell RNA sequencing to predict cancer drug efficacy. This tool, detailed in a recent study published in Nature Cancer, marks a significant advancement in personalizing cancer treatment, potentially improving outcomes by targeting individual tumor cell subpopulations.

Please follow the link to learn more.

Novartis Announces Breakthrough in Rare Kidney Disease Treatment with Fabhalta

Novartis has shared promising results from their Phase III APPLAUSE-IgAN clinical trial, revealing significant proteinuria reduction in patients with IgA nephropathy (IgAN) through the use of Fabhalta® (iptacopan). This marks the first time a treatment targeting the alternative complement pathway has shown such efficacy.

Please follow the link to learn more.

Pioneering Stem Cell Therapy for Alzheimer’s Disease Begins Human Trials

Regeneration Biomedical has initiated a groundbreaking Phase I trial, injecting a novel stem cell therapy, RB-ADSC, directly into the brain of patients with mild-to-moderate Alzheimer’s disease. This first-in-human trial aims to bypass the blood-brain barrier, which often limits the effectiveness of traditional treatments.

Please follow the link to learn more.

Rezdiffra Approval Sheds Light on the Challenges of NASH Diagnosis and Fibrosis Identification

The recent approval of Rezdiffra (resmetirom), a novel therapeutic for the treatment of non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, marks a significant milestone in the fight against this increasingly prevalent liver disease. However, the journey to this point underscores the persistent challenges faced by healthcare professionals in diagnosing NASH and identifying fibrosis levels in affected patients.

Please follow the link to learn more.

AI Boosts Accuracy in Skin Cancer Diagnoses

Stanford Medicine has published a new study on the use of artificial intelligence in diagnosing skin diseases. This AI system has shown to significantly improve the accuracy of diagnoses, potentially revolutionizing dermatological care. The researchers highlight how AI can enhance the ability to differentiate between benign and malignant lesions, aiding in early and more accurate treatments.

Please follow the link to learn more.

First Combined Heart Pump and Pig Kidney Transplant Achieved

Surgeons at NYU Langone Health have performed the first transplant combining a mechanical heart pump and a gene-edited pig kidney. This procedure offers a new hope for patients like Lisa Pisano, who are ineligible for standard transplants due to complex health conditions.

Please follow the link to learn more.

Сlinical Trials in Georgia 2024

Georgia, a country nestled between Eastern Europe and Western Asia, has emerged as a promising destination for clinical trials. With its strategic location and favorable regulatory environment, Georgia has become increasingly attractive to international sponsors seeking to conduct innovative research projects.

Please follow the link to learn more.